Search Results
Results found for "Gator Bio"
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
Instead, they must ask how the assay itself can be tuned to better mirror the biological and clinical Kenakin Content trusted by biotech, pharma & academia 💎 $2999/year — one conference cost = a full
- Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization
Practical sessions on GPCR internalization and soluble proteins; core meetings from GPCR Forum to Biophysics arguing about “potency vs. effect size vs. duration,” this is your playbook for aligning strategy with biology with your topic suggestions 🆕 Weekly new releases to stay ahead of the science 🧠 Content built for biotech harder question: What if you could measure receptor internalization in native cells, without distorting biology GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
with your topic suggestions 🆕 Weekly new releases to stay ahead of the science 🧠 Content built for biotech
- Optimizing HTRF Assays with Fluorescent Ligands: Time-Resolved Fluorescence in GPCR Research
By combining deep expertise in GPCR biology with advanced fluorescence chemistry, Celtarys custom-developed
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
Orphan GPCRs in Neurodegenerative Disorders: Integrating Structural Biology and Drug Discovery Approaches Curr Issues Mol Biol. 2024 Oct 19;46(10):11646-11664. Biomed Pharmacother. 2018 Feb;98:222-232. doi: 10.1016/j.biopha.2017.12.056 Azam S, Haque ME, Jakaria Orphan GPCRs in Neurodegenerative Disorders: Integrating Structural Biology and Drug Discovery Approaches Curr Issues Mol Biol. 2024 Oct 19;46(10):11646-11664. doi: 10.3390/cimb46100691 Navarro G, Sotelo E
- How to Design GPCR Drugs That Work in Vivo: Strategy, Tools, and Insights
GPCR , our mission is simple but urgent: Accelerate GPCR biology and drug discovery by connecting scientists GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need tools, translational strategy, classified updates, and curated jobs—trusted by scientists, teams, and biotech
- Why Opposing Processes Matter for Your Next GPCR Drug
toward the clinic, this is a blueprint for building a more reliable evidence base—one that accounts for biology
- How Advanced GPCR Kinetics Sharpen Decision Making (and Save You Time)
2025 (Boston, Sept 24‑25), including GPCR‑Track breakout sessions; panel opportunities to engage with biophysics and structural biology leaders. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need
- GPCR Drug Discovery at Discovery on Target: Why This Track Is About More Than Receptors
Discovery at Discovery on Target 2025 — The Track You Can’t Miss If you work in drug discovery or biotech Over the years, we’ve built a global network of researchers, biotech leaders, and pharma innovators who These sessions bridge structural biology , computational modeling , and clinical translation — with together. 🚨 Mark your calendar for the GPCR Happy Hour Join us at GPCR Happy Hour , where scientists, biotech
- The Five Traps of Ignoring Kinetics
But biology isn’t tidy.
- Mechanism vs. Assumption: A Model-First Path to Getting GPCR MoA Right
Industry insights: Biopharma returns to MC4R; Recursion completes Exscientia acquisition, signaling , SNAP/Halo tags, and fluorescent ligands tied to pharmacophores—plus how to choose probes for your biological Yamina Berchiche to discuss: 🔹 Why PAR1 and PAR2 are such unique GPCRs 🔹 What structural biology is GPCR scientists, translational pharmacologists, biotech discovery teams, platform company leaders, and
- Integrating Fluorescent Ligands into Flow Cytometry: Enhancing GPCR Analysis Beyond Traditional Antibody Staining
Biomedicines. 2021 Nov 4;9(11):1613. Biomedicines. 2021 Nov 4;9(11):1613. doi: 10.3390/biomedicines9111613 University of Virginia Flow Cytometry Methods Mol Biol. 2023;2580:89-114. doi: 10.1007/978-1-0716-2740-2_5
- How to Use Statistical Methods to Strengthen Every GPCR Drug Discovery Decision
Ajay Yekkirala shares the journey from academic pharmacologist to biotech entrepreneur—bridging curiosity Understand how AI/ML and GPCR biology meet to unlock safer drugs. When the global biotech crowd lands in Boston for Discovery on Target. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need
- Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells
membranes transmitting signals from the outside into the cells, making them an essential target in biomedical The biological context (live or fixed cells), the spatial temporal resolution and other experimental
- GPCR Happy Hour – Boston, Sept 2025
When the biotech world gathers in Boston, this is where the real conversations begin. Every September, Boston welcomes the global biotech and drug discovery community. Why It Matters Connect with peers across biotech, CROs, and investment who are driving discovery forward Meet both the global biotech community and Boston’s local innovators in one room Be part of Dr. The company has long-standing expertise in G protein–coupled receptor (GPCR) biology—one of the most
- Allosteric Binding Demystified: Smarter GPCR Drug Discovery
Career opportunities: Postdocs in GPCR biophysics and assay development; industry scientist roles at BPS Bioscience. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need
- The Hidden Driver of GPCR Drug Success: Why Target Residence Time Matters More Than You Think
about key global conferences and symposia focusing on GPCRs, neuropharmacology, drug discovery, and biophysics opportunities: Explore a selection of high-level job openings in high-throughput screening, research, biologics development, clinical operations, and biostatistics within leading organizations. Shape the next generation of cellular biochemistry research. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need
- Fluorescence Polarization in GPCR Research
Nanomaterials Used in Fluorescence Polarization Based Biosensors.
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
Why This Research Matters Beyond the Lab Catherine’s findings bridge the gap between basic receptor biology They’re rewriting the biology of overdose.
- Why “Displacement” Misleads You: Allosteric Binding Demystified
increases radioligand binding but suppresses functional response, it’s not broken pharmacology—it’s biology
- Advantages of Fluorescent Probes in GPCR Assays
Biomed Pharmacother. 2022 Sep;153:113408. doi: 10.1016/j.biopha.2022.113408. ACS Chem Biol. 2014 Sep 19;9(9):1918-28. doi: 10.1021/cb5004042. Biochim Biophys Acta. 2014 Jan;1838(1 Pt A):15-33. doi: 10.1016/j.bbamem.2013.09.005.
- Radioligands vs. Fluorescent Ligands: Binding Assays
Understanding receptor-ligand interaction is key in drug discovery and biomedical research. binding assays, they can also be used to study receptor density, binding sites and ligand kinetics in biological Methods Cell Biol. 2016;132:191-215. doi: 10.1016/bs.mcb.2015.11.004.
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
parameters of PL-384 binding to D3 receptors from competition binding experiment data by global systems biology Journal of Biological Chemistry 2005 , 280 (3), 2176–2185. https://doi.org/10.1074/jbc.M410385200 Biochemical Pharmacology 1973 , 22 (23), 3099–3108. https://doi.org/10.1016/0006-2952(73)90196-2 . Biochimica et Biophysica Acta (BBA) - Biomembranes 2014 , 1838 (1), 372–381. https://doi.org/10.1016
- Conjugation Strategies for Probe Development
with proteins, DNA, etc, thanks to its reaction with the free amino groups present in these biomolecules This conjugation is very useful for tagging biomolecules and can also be used to develop fluorescent as the presence of the copper catalyst, which has to be removed completely, otherwise it can quelate biomolecules Chapter Three - Bioconjugated Materials in the Development of Subunit Vaccines. Bioconjugate Chem. 2015 , 26 (1), 145–152. https://doi.org/10.1021/bc5005262 .
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
And every time your Head of Biology spends each night copy-pasting data instead of thinking about the
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
From restricted tissue diffusion to PK–PD dissociation, Kenakin equips you with the kinetic models and biological
- How Fast Does a Drug Work?
Two compounds can show identical affinities on paper, but their biological outcomes can differ dramatically
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before It’s Too Late
🔹 Spot the opportunity → Why Catalio is betting big when others pull back Amid biotech slowdowns
- Your GPCR Program Decisions Depend on Good Data Interpretation
productive lab—it accelerated outcomes and laid the cultural foundation for the next generation of biotech insights from major conferences, emerging research, and expert commentary Whether you’re a pharmacologist, biotech
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
Corner delivers this week: high-impact insight into GPCR allostery, crafted for pharmacologists and biotech nuance into better decision-making. 🔍 This Week in Premium: Sneak Peek Industry insights: Strategic biotech publications: CXCL12 dimer impact on AML migration, mechanosensitive behavior in GPCRs, and in vivo APLNR biosensor This is where funders, peers, and biotech scouts are watching. GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who






























